Deadline Approaching: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. following allegations by Culper Research of channel stuffing, undisclosed related party transactions, and inflated revenue growth. The stock fell 29.1% on March 24-25, 2026, after the report alleged the company induced distributors to stock excess inventory using rebates and extended payment terms to artificially boost reported revenues. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 have until August 10, 2026 to file a lead plaintiff motion.